Lexeo Therapeutics
LXEO
146 hedge funds and large institutions have $759M invested in Lexeo Therapeutics in 2025 Q4 according to their latest regulatory filings, with 47 funds opening new positions, 61 increasing their positions, 26 reducing their positions, and 9 closing their positions.
422% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 9
135% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 26
132% more capital invested
Capital invested by funds: $327M → $759M (+$432M)
34% more funds holding
Funds holding: 109 → 146 (+37)
13.42% more ownership
Funds ownership: 91.34% → 104.76% (+13%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less call options, than puts
Call options by funds: $136K | Put options by funds: $143K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$45.6M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$43.5M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$30.1M |
| 4 |
BlackRock
New York
|
+$25M |
| 5 |
State Street
Boston,
Massachusetts
|
+$24.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$20.8M |
| 2 |
Millennium Management
New York
|
-$12.8M |
| 3 |
DCP
D1 Capital Partners
New York
|
-$6.5M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
-$6.12M |
| 5 |
Janus Henderson Group
London,
|
-$5.44M |
LXEO Hedge Fund Activity: Q4 2025 in Review
146 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Lexeo Therapeutics (LXEO) for Q4 2025, worth a combined $759M — up 132% from $327M a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new LXEO positions and 9 closed out — a net gain of 38 holders — while 61 added to existing stakes and 26 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $45.6M. The largest seller was Balyasny Asset Management, cutting an estimated $20.8M.
- 146 institutional investors held Lexeo Therapeutics (LXEO) as of Q4 2025, up from 109 in Q3 2025.
- Funds reported $759M of Lexeo Therapeutics stock for Q4 2025, up 132% quarter-over-quarter.
- 47 funds opened new Lexeo Therapeutics positions in Q4 2025 and 9 closed out, a net change of +38 holders.
- The largest Lexeo Therapeutics buyer in Q4 2025 was RA Capital Management, an estimated $45.6M added.
- The largest Lexeo Therapeutics seller in Q4 2025 was Balyasny Asset Management, an estimated $20.8M sold.
Based on aggregated 13F filings for Q4 2025.